SCHEMBL20177003

SCHEMBL20177003

CN(Cc1ccc(Br)cn1)C(=O)OC(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 6/20 0.42
SLC6A4 P31645 6/20 0.42
SSTR4 P31391 1/20 0.39
HTR2A P28223 1/20 0.38
DGAT1 O75907 1/20 0.38
CACNA1G O43497 1/20 0.37
CACNA1B Q00975 1/20 0.37
CACNA1C Q13936 1/20 0.37
MCHR1 Q99705 2/20 0.36
FPR3 P25089 1/20 0.36
FPR2 P25090 1/20 0.36
GBA1 P04062 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
AAK1 Q2M2I8 1/20 0.35
RAB9A P51151 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29686229 1.00 HTR2C (0.42) HTR2CSLC6A4SSTR4HTR2ADGAT1
SCHEMBL31420072 0.83 AAK1 (0.38) SSTR4DGAT1MCHR1GBA1HDAC1
SCHEMBL31754515 0.83 AAK1 (0.38) SSTR4DGAT1MCHR1GBA1HDAC1
SCHEMBL29990877 0.82 CACNA1G (0.39) HTR2CSLC6A4SSTR4HTR2ADGAT1
SCHEMBL2847467 0.82 HCAR3 (0.48) HTR2CSLC6A4HTR2AHDAC1HDAC8
SCHEMBL31419262 0.81 SSTR4 (0.36) HTR2CSLC6A4SSTR4DGAT1MCHR1
SCHEMBL25523616 0.81 SSTR4 (0.42) SSTR4DGAT1MCHR1GBA1HDAC1
SCHEMBL23410434 0.80 HTR2C (0.44) HTR2CSLC6A4SSTR4HTR2ACACNA1G
SCHEMBL29899115 0.80 HTR2C (0.44) HTR2CSLC6A4SSTR4HTR2ACACNA1G
SCHEMBL19739531 0.79 ALDH1A1 (0.44) MCHR1GBA1RAB9AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388585-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES INC (US) 2025-12-25 US disclosed
US-12448388-B2 PRMT5 inhibitors and uses thereof GILEAD SCIENCES, INC. (US) 2025-10-21 US disclosed
CN-119562812-A Substituted N- (pyridin-2-yl) acetamide derivatives as CDK12/13 inhibitors 奥里吉恩肿瘤学有限公司 2025-03-04 CN disclosed
US-20250051338-A1 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-02-13 US disclosed
CN-119013277-A TYK2 degrading agent and application thereof 凯麦拉医疗公司 2024-11-22 CN disclosed
US-20240376110-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES, INC. 2024-11-14 US disclosed
EP-4423086-A1 TYK2 DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2024-09-04 EP disclosed
US-20230183212-A1 INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF STINGRAY THERAPEUTICS INC (US) 2023-06-15 US disclosed
WO-2023076161-A1 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-05-04 WO disclosed
WO-2023076161-A1 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-05-04 WO disclosed
WO-2022115377-A1 TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS AMGEN INC. (US) 2022-06-02 WO disclosed
EP-3535258-B1 SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2021-11-24 EP disclosed
WO-2018093569-A1 SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2018-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388585-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT1, PRMT5, PRMT6 HTR2C 4179/4885SLC6A4 4460/4885SSTR4 4617/4885
US-20240376110-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT9 HTR2C 4597/4885SLC6A4 4507/4885SSTR4 4785/4885
US-20250051338-A1 TYK2 DEGRADERS AND USES THEREOF TYK2, DYRK2, DYRK1A HTR2C 2094/4885SLC6A4 4739/4885SSTR4 4001/4885
US-12448388-B2 PRMT5 inhibitors and uses thereof PRMT5, PRMT1, PRMT9 HTR2C 4597/4885SLC6A4 4507/4885SSTR4 4785/4885
US-20230183212-A1 INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF ENPP1, ENPP3, PPA1 HTR2C 4805/4885SLC6A4 4232/4885SSTR4 4068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.